Alexandre Larivée
0009-0009-1470-5128
Paraza Pharma (Canada)
1 paper found
Refreshing results…
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Missing publications? Search for publications with a matching author name.